Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non–small cell lung cancer: A network meta‐analysis of randomized trials-Reference-Cited by-同舟云学术

Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non–small cell lung cancer: A network meta‐analysis of randomized trials

Published:2020-10-29 Issue:5 Volume:127 Page:709-719
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Pathak Ranjan¹^ORCID,De Lima Lopes Gilberto²,Yu Han³,Aryal Madan Raj³⁴,Ji Wenyan³,Frumento Katherine Stemmer⁵,Wallis Christopher J. D.⁶^ORCID,Klaassen Zachary⁷⁸^ORCID,Park Henry S.⁹^ORCID,Goldberg Sarah B.¹^ORCID

Affiliation:

1. Division of Medical Oncology Department of Medicine Yale School of Medicine New Haven Connecticut

2. Department of Medical Oncology Sylvester Comprehensive Cancer Center University of Miami Miami Florida

3. Department of Biostatistics and Bioinformatics Roswell Park Comprehensive Cancer Center Buffalo New York

4. Department of Medicine (Medical Oncology) Roswell Park Comprehensive Cancer Center Buffalo New York

5. Clinical Information Services Harvey Cushing/John Hay Whitney Medical LibraryYale School of Medicine New Haven Connecticut

6. Department of Urology Vanderbilt University Medical Center Nashville Tennessee

7. Division of Urology Department of Surgery Medical College of GeorgiaAugusta University Augusta Georgia

8. Georgia Cancer Center Augusta University Augusta Georgia

9. Department of Therapeutic Radiology Yale School of Medicine New Haven Connecticut

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33269

Reference40 articles.

1. The biology and management of non-small cell lung cancer

2. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

3. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

4. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

5. US Food and Drug Administration.FDA approves nivolumab plus ipilimumab for first‐line mNSCLC (PD‐L1 tumor expression ≥1%). Published May2020. Accessed May 20 2020.https://www.fda.gov/drugs/drug‐approvals‐and‐databases/fda‐approves‐nivolumab‐plus‐ipilimumab‐first‐line‐mnsclc‐pd‐l1‐tumor‐expression‐1

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Male sex and pretreatment weight loss are associated with poor outcome in patients with advanced non-small cell lung cancer treated with immunotherapy: a retrospective study;Scientific Reports;2023-10-09

2. Algorithme thérapeutique des CBNPC sans mutation addictive;Revue des Maladies Respiratoires Actualités;2023-10

3. Platinum Twin and Triplet Drugs Improve Chemoimmunotherapy;Journal of Medicinal Chemistry;2023-09-04

4. Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis;Biomedicines;2023-06-26

5. Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non–small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90%;Clinical Lung Cancer;2023-05